- Source type
- Article
- Access type
- Publisher
- Publisher
- San Francisco Chronicle
- Added
- 2026-07-09
Trust profile
VV Source Trust Matrix v1.0
VV Source Trust Matrix v1.0 asks whether this source is trustworthy for the claim lane being used, not whether every possible claim from it is equally strong.
60
General published source
- Publisher type
- General media
- Bias profile
- Elevated
This source is strongest for consumer context and regulatory status and weaker for safety and trial discovery.
VV Source Fit Score 1.0
Fit by use case
Fit scores are role-specific. A source can be excellent for one claim lane and weak for another.
- Regulatory status
- 54/100
- Weak Support
- Clinical outcomes
- 54/100
- Weak Support
- Mechanism
- 54/100
- Weak Support
- Safety
- 54/100
- Weak Support
- Consumer context
- 67/100
- Context Source
- Trial discovery
- 54/100
- Weak Support
Best used for
- Context
- Public narrative
Weak for
- Clinical claims
- Safety conclusions
- Regulatory status
Used in Viral Vitalism
Tiny Retinal Implant Helped Some Blind Patients Read Again
Roles: Background
Show section-level references
- The PRIMA retinal implant, paired with camera-equipped glasses and training, helped many participants with severe age-related macular degeneration regain limited central visual function, including reading ability. This is partial prosthetic vision restoration, not normal vision, not a cure for blindness, and not yet broadly approved in the U.S.Patient-facing reporting; add primary device/trial source before publishing as a rapid brief.
Related studies
No structured study record is currently attached to this source.
Related sources
ClinicalTrials.gov: KIO-301 ABACUS-1 trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 84
- Publisher
- ClinicalTrials.gov
- Access
- Official
- Usage
- 0 connections
FDA clears first over-the-counter continuous glucose monitor
Official FDA clearance source for the OTC CGM boundary: intended population, hypoglycemia limitation, and medical-decision warning.
- Trust score
- 94
- Publisher
- U.S. Food and Drug Administration
- Access
- Official
- Usage
- 7 connections
Reuters Health Rounds: PRIMA retinal implant context
Older independent context; should not be treated as a new July 2026 news peg.
- Trust score
- 60
- Publisher
- Reuters
- Access
- Publisher
- Usage
- 1 connection
The Guardian: electronic implant restoring sight report
Older corroborating report; useful for context but not a fresh July 2026 trigger by itself.
- Trust score
- 60
- Publisher
- The Guardian
- Access
- Publisher
- Usage
- 1 connection
Medical Xpress / University of Adelaide: photoswitch drug first human trial
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 60
- Publisher
- Medical Xpress / University of Adelaide
- Access
- Publisher
- Usage
- 0 connections
Nature Medicine: Intravitreal photoswitch therapy in advanced retinitis pigmentosa
Canonicalized from June 30, 2026 rapid-brief batch.
- Trust score
- 88
- Publisher
- Nature Medicine
- Access
- Publisher
- Usage
- 0 connections